首页> 外文期刊>Nature cancer. >Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
【24h】

Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

机译:更正:出版商ERK1/2磷酸化预测生存anti-PD-1后免疫治疗在复发胶质母细胞瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Correction to: Nature Cancer https://doi.org/10.1038/s43018-021-00260-2, published online 29 November 2021. In the version of this article initially published, there was an error in the author affiliations for Gerson Rothschild and Uttiya Basu. Both authors are affiliated with the Department of Microbiology and Immunology, Columbia University, New York, NY, USA, and not, as originally published, University of Rennes 1. The affiliations have been updated in the HTML and PDF versions of the article.
机译:修正:自然癌症https://doi.org/10.1038/s43018 - 021 - 00260 - 2,2021年11月29日在线发表。本文最初发表的,有一个错误Gerson作者的从属关系罗斯柴尔德和Uttiya苏。隶属于美国微生物学和免疫学,哥伦比亚大学,纽约,美国纽约,而不是出版,雷恩大学的1。被更新的HTML和PDF版本的篇文章。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号